Jason Kaplan

5PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 05, 2026
Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: results from EV-202 cohort 9.

|Feb 19, 2025
Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Paul L Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg

|Oct 31, 2024
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Paul L Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg

|Sep 30, 2021
Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.

David Chan, Jason Kaplan, Gary Gordon

|Aug 02, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.

William B Pearse, Adam M Petrich, Leo I Gordon

Pageof 1

Frequent Collaborators

3 joint publications

Paul L Swiecicki

3 joint publications

Ari Joseph Rosenberg

3 joint publications

Takao Fujisawa

3 joint publications

Justine Yang Bruce